Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees.  The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Novavax, Inc. adalah perusahaan bioteknologi yang terlibat dalam penemuan, pengembangan, dan komersialisasi vaksin rekombinan. Perusahaan ini berkantor pusat di Gaithersburg, Maryland dan saat ini mempekerjakan 952 karyawan penuh waktu. Perusahaan berfokus pada mengatasi tantangan kesehatan global melalui vaksin-vaksinnya dan platform teknologi yang terbukti, termasuk nanopartikel berbasis protein dan adjuvan Matrix-M. Matrix-M dapat digunakan untuk menciptakan vaksin untuk berbagai penyakit guna membantu mengatasi beberapa tantangan kesehatan yang mendesak. Adjuvan Matrix-M yang hak milik, ketika ditambahkan ke vaksin, telah terbukti membantu menghasilkan respons imun yang lebih kuat dan bertahan lebih lama. Teknologi nanopartikel berbasis protein rekombinan ini telah terbukti sangat imunogenik. Platform teknologinya digunakan dalam vaksin COVID-19 yang telah disetujui dan vaksin malaria R21/Matrix-M adjuvant. Program-program tahap akhir termasuk kandidat vaksin COVID-19-Influenza dan kandidat vaksin influenza. Vaksin malaria R21/Matrix-M adjuvant adalah vaksin malaria yang dikembangkan oleh mitranya. Perusahaan menyediakan adjuvan Matrix-M untuk digunakan dalam berbagai program di tahap pra-klinis dan klinis, serta penyelidikan pra-klinis.

Novavax

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

ASML

SPDR S&P500 ETF

Netflix

Palantir

Bank of America

AbbVie

Costco

Alibaba

Home Depot

Procter & Gamble

Cisco

Chevron

Vanguard Total Stock Market ETF

UnitedHealth Group

Coca-Cola

General Electric

Wells Fargo

Morgan Stanley

Caterpillar

AstraZeneca

Micron Technology

Goldman Sachs

American Express

Toyota

Novartis

Merck

Salesforce

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shell

Shopify

Intuitive Surgical

Invesco QQQ Trust

PepsiCo

Citigroup

Lam Research

Intel

Uber

Disney

QUALCOMM

Linde PLC

Blackstone

Intuit

AT&T

Amgen

ServiceNow

Verizon

NextEra Energy

Charles Schwab

Sony

BlackRock

Accenture

Texas Instruments

Booking Holdings

Danaher

Arista Networks

Banco Santander

Boeing

S&P Global

Gilead Sciences

Toronto-Dominion Bank

Capital One

Pfizer

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Adobe

Lowe's

Palo Alto Networks

Novavax Stock

About Novavax

Key Statistics